Vertex Pharmaceuticals Incorporated (VRTX)
After hours:
| Previous close | 401.08 |
| Open | 402.30 |
| Bid | 382.63 x 100 |
| Ask | 402.54 x 100 |
| Day's range | 401.02 - 407.59 |
| 52-week range | 320.01 - 448.40 |
| Volume | |
| Avg. volume | 1,029,693 |
| Market cap | 104.03B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 28.89 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
UPDATE 1-Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its blockbuster cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Vertex reported adjusted earnings per share of $4.76 on revenue of $2.69 billion, topping market estimates $4.06 on revenue of $2.58 billion, according to LSEG data, for the quarter ended March 31.
- GuruFocus.com
Vertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Expansions
Comprehensive Analysis of Vertex Pharmaceuticals' Financial Performance and Strategic Initiatives
- Zacks
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates
Vertex (VRTX) delivered earnings and revenue surprises of 16.10% and 5.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
